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Abstract: Cannabigerol (CBG) and cannabichromene (CBC) are non-psychoactive cannabinoids
that have raised increasing interest in recent years. These compounds exhibit good tolerability and
low toxicity, representing promising candidates for drug repositioning. To identify novel potential
therapeutic targets for CBG and CBC, an integrated ligand-based and structure-based study was
performed. The results of the analysis led to the identification of CBG as a low micromolar inhibitor
of the Enoyl acyl carrier protein (ACP) reductase (InhA) enzyme.
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1. Introduction
In recent decades, increasing research efforts have been directed towards identifying novel
drugs based on unexplored chemical scaffolds. However, the rate of drug approvals has become
stable, with only a small number of the developed chemical entities entering in therapeutic use,
or even in clinical trials [1–4]. As a consequence, discovery strategies have been adopted to reduce
failures, time efforts and expenses; in this context, drug repurposing has become one of the most
successful strategies to reduce failures typically associated with drug discovery. Drug repurposing
consists of identifying novel therapeutic uses for already approved drugs and/or clinical candidates,
as it might allow circumventing preclinical optimization issues, such as adverse toxicology profiles.
Although most drug repurposing success stories derive from serendipity, current efforts are mainly
directed toward rationally predicting repurposing through systematic analysis of bioactivity data with
computational approaches. Indeed, in silico methods have been successfully used to help delineating
new drug repurposing opportunities [5–7]. Several ligand-based and structure-based virtual screening
approaches are currently available to support drug discovery programs. However, each in silico
method alone could not be sufficiently able to model the complex interplay between drugs and targets,
because of intrinsic limitations [8]. Therefore, the combination of ligand-based and structure-based
methods is expected to: (i) provide more robust results; (ii) help overcoming intrinsic limitations of
single approaches, and; (iii) complement each other in a drug discovery workflow [8–10]. Interestingly,
the combination of ligand-based and structure-based approaches have already been successfully used
to identify molecular targets for Mycobacterium tuberculosis phenotypic hits [11].
At present, most drug repurposing studies rely on the analysis of bioactivity data of compounds
deriving from chemical synthesis. However, other valuable opportunities might come from natural
products [12–14]. Natural products are characterized by a great structural diversity, and can provide
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novel chemical entities to be properly optimized in drug discovery campaigns. In this context,
cannabinoids, which are terpenophenolics widely present in different varieties of Cannabis sativa L.,
are a very interesting class of bioactive compounds [15]. In particular, the pharmacological profile of
non-psychoactive cannabinoids makes them the leading actors of the vast majority of scientific papers
related to the fiber-type variety, which is commonly known as industrial hemp or hemp [16]. Among
these compounds, cannabidiol (CBD) represents the best known example from a pharmaceutical point
of view, possessing antioxidant, anti-inflammatory, antibacterial, anti-proliferative, neuroprotective
and anticonvulsant properties [15,16]. Cannabigerol (CBG) and cannabichromene (CBC) are other
non-psychoactive cannabinoids (Figure 1a), which can be found in C. sativa inflorescences; they are
both characterized by antibacterial activity, together with anti-inflammatory and anti-proliferative
properties [17].
Since the above-mentioned compounds represent good candidates for drug repositioning, the aim
of this work was to develop and apply an integrated ligand- and structure-based in silico procedure
to unveil possible biological targets of non-psychoactive cannabinoids to be used in future drug
discovery campaigns.
2. Results and Discussion
To identify potential targets of CBG and CBC that could be of therapeutic interest, a 3D ligand-based
virtual screening was first performed within the DrugBank database [18]. Indeed, this approach has
already demonstrated to provide valuable results for drug repurposing, allowing the identification
of structurally unrelated compounds with similar bioactivities [19]. Among the available databases,
the DrugBank was selected because it provides a comprehensive list of approved and investigational
drugs, with trustful bioactivity annotations on relevant therapeutic targets. The DrugBank was first
prepared for the 3D ligand-based similarity analyses (see “Materials and Methods” section for details).
Then, the DrugBank compounds were subjected to a 3D similarity screening against the generated
CBG and CBC multi-conformer queries. This analysis allowed prioritizing potential therapeutic targets
according to the degree of similarity of CBG and CBC with respect to the DrugBank compounds. Visual
inspection of the predicted alignments allowed the identification of the Enoyl acyl carrier protein (ACP)
reductase (InhA) enzyme as a potential target for both CBG and CBC. In fact, according to the ligand
alignments, both cannabinoids resulted to be similar to 5-pentyl-2-phenoxyphenol (5PP, DrugBank ID:
DB07178) (Figure 1b), which is a small molecular weight inhibitor of InhA [20]. Ligand similarities are
reported in Table S1 of the Supporting Information. In particular, according to the obtained alignments,
the 5-pentyl-1,3-dihydroxyphenyl moiety of CBG overlapped well with the 5-pentyl-2-phenoxy group
of 5PP, while the 3,7-dimethylocta-2,6-dienyl moiety of CBG provides looser superimposition with the
phenyl group of 5PP. Regarding CBC, the n-pentyl-chromene-5-ol group provided a less favorable
overlap with the 5-pentyl-2-phenoxy group of 5PP, this moiety occupying significant larger volume
with respect to the hydroxyphenyl group of 5PP.
Good ligand-based alignments of CBC and CBG with other cannabinoids reported in the DrugBank
database were also found (see Table S1 in the Supporting Information), such as cannabidiol (DrugBank
ID: DB09061) and dronabinol (DrugBank ID: DB00470), which have recently been approved for treating
epilepsy in children and nausea associated with cancer chemotherapy, respectively [21,22]. However,
we decided to focus our attention to the InhA enzyme, which is a validated target of well-known
antitubercular drugs [23,24].
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Figure 1. Chemical structures and ligand-based alignments of CBG and CBC predicted with ROCS 
[25]. Specifically, (a) reports the structures of CBG, 5PP and CBC. The chiral center in CBC is 
highlighted with a red star. (b) reports the shape-based alignment obtained for CBG (dark teal sticks) 
and the S stereoisomer of CBC (dark grey sticks) with the 5PP (orange thinner sticks) compound. 
Although CBC and CBG showed good shape similarity with the 5PP inhibitor, the two 
compounds were also docked in the InhA crystal structure (PDB code: 2B36) [20], as described in the 
“Material and Methods” section. This analysis made it possible to assess whether the investigated 
compounds also possess good steric and electrostatic complementarity with the InhA binding site. 
The 2B36 crystal structure was preferred among others available for InhA, because the enzyme is in 
complex with 5PP [20]. Indeed, the selection of suitable receptor conformations for docking by means 
of the similarity between the crystallographic and the screening ligands is among one of the most 
used methods to improve structure-based virtual screening results [9,26]. Docking analyses were 
performed with Glide and the Induced Fit Docking protocol available with the Schrödinger suite 
2018-3, [27,28]. At this stage of the analysis, different docking protocols, i.e., rigid (Glide) and flexible 
(Induced Fit), were performed to evaluate whether small structural changes, due, e.g., to receptor 
flexibility of InhA, might affect ligand binding [29]. To assess the ability of the docking protocol to 
reproduce the native orientation of the crystallographic ligand, redocking of 5PP into its own 2B36 
crystal structure was first performed as a control (see Figure S1 in the Supporting Information), with 
the evaluated Root Mean Square Deviation (RMSD) being below 2.0 Å. Then, docking of CBG and 
CBC was performed. A visual inspection of the docking complexes with the best score predicted with 
Glide showed that CBG could accommodate into the InhA binding site by adopting an orientation 
similar to that of 5PP (Figure 2a). Interestingly, one of the hydroxyl groups of CBG is involved in a 
H-bond network of interactions with both Tyr158 and the 2′-hydroxyl group of NADH, similarly to 
5PP [20]. These interactions are recognized to be particularly important for the catalytic activity of 
InhA [20,30]. The phenol ring provides stacking interactions with the nicotinamide ring of NADH. 
The 3,7-dimethylocta-2,6-dienyl moiety was predicted to be accommodated between the Phe97, 
Met103 and the Ala198 residues, while the n-pentyl group binds near to the Phe149, Met155, Tyr158 
and Leu218 residues, establishing hydrophobic contacts. 
Different results were obtained for CBC, for which structure-based predictions did not agree 
with the ligand-based alignment. In particular, the S stereoisomer of CBC, which provided the best 
score in the docking calculations, was predicted to bind InhA with a binding mode that is head-to-
tail with respect to that of 5PP in the crystal structure (Figure 2b and Figure S2). The different binding 
mode likely originates from steric repulsion of the 2-(4-methylpent-3-enyl) moiety of CBC with the 
Figure 1. Chemical structures and ligand-based alignments of CBG and CBC predicted with ROCS [25].
Specifically, (a) reports the structures of CBG, 5PP and CBC. The chir l center in CBC is highlighted
with a red star. (b) reports the s ape-based alignment obtained for CBG (dark teal sticks) a d the S
stereoisomer of CBC ( ark grey sticks) with t e 5PP (orange thin er sticks) compound.
Although CBC and CBG showed good shape similarity with the 5PP inhibitor, the two compounds
were also docked in the InhA crystal structure (PDB code: 2B36) [20], as described in the “Material and
Methods” section. This analysis made it possible to assess whether the investigated compounds also
possess good steric and electrostatic complementarity with the InhA binding site. The 2B36 crystal
structure was preferred among others available for InhA, because the enzyme is in complex with
5PP [20]. Indeed, the selection of suitable receptor conformations for docking by means of the similarity
between the crystallographic and the screening ligands is among one of the most used methods to
improve structure-based virtual screening results [9,26]. Docking analyses were performed with Glide
and the Induced Fit Docking protocol available with the Schrödinger suite 2018-3, [27,28]. At this stage
of the analysis, different docking protocols, i.e., rigid (Glide) and flexible (Induced Fit), were performed
to evaluate whether small structural changes, due, e.g., to receptor flexibility of InhA, might affect
ligand binding [29]. To assess the ability of the docking protocol to reproduce the native orientation of
the crystallographic ligand, redocking of 5PP into its own 2B36 crystal structure was first performed as
a control (see Figure S1 in the Supporting Information), with the evaluated Root Mean Square Deviation
(RMSD) being below 2.0 Å. Then, docking of CBG and CBC was performed. A visual inspection of the
docking complexes with the best score predicted with Glide showed that CBG could accommodate into
the InhA binding site by adopting an orientation similar to that of 5PP (Figure 2a). Interestingly, one of
the hydroxyl groups of CBG is involved in a H-bond network of interactions with both Tyr158 and the
2′-hydroxyl group of NADH, similarly to 5PP [20]. These interactions are recognized to be particularly
important for the catalytic activity of InhA [20,30]. The phenol ring provides stacking interactions
with the nicotinamide ring of NADH. The 3,7-dimethylocta-2,6-dienyl moiety was predicted to be
accommodated between the Phe97, Met103 and the Ala198 residues, while the n-pentyl group binds
near to the Phe149, Met155, Tyr158 and Leu218 residues, establishing hydrophobic contacts.
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Figure 2. Docking poses of CBG and CBC into the 2B36 crystal structure predicted with Glide.
Specifically, (a,b) report the predicted binding modes of CBG (dark teal sticks) and the S enantiomer of
CBC (dark grey sticks) into the InhA receptor, respectively. NADH is reported as raspberry sticks.
Differ nt results were obtained for CBC, for which structure-based predictions did not agree
with the ligand-based alignment. In particular, the S stereoisomer of CBC, which provided the best
score in the docking calculations, was predicted to bind InhA with a binding mode that is head-to-tail
with respect to that of 5PP in the crystal structure (Figure 2b and Figure S2). The different binding
mode likely originates from steric repulsion of the 2-(4-methylpent-3-enyl) moiety of CBC with the
NADH cofactor. In this binding mode, the S stereoisomer of CBC is engaged in H-bonds with both
Tyr158 and the 2′-hydroxyl group of NADH, such as 5PP [20]. On the contrary, docking of the R
enantiomer of CBC into the 2B36 crystal structure provided a binding pose that did not establish
relevant H-bond interactions with the InhA binding site residues or NADH; therefore, this stereoisomer
was not further considered. To further refine the results obtained with Glide, a rescoring of the
predicted docking poses was performed with BEAR [31]. Indeed, BEAR has already demonstrated
to improve docking results in a variety of virtual screening campaigns and retrospective validations,
including also the enoyl ACP reductase target [32–35]. Therefore, it represents a valuable approach to
refine docking results. Interestingly, BEAR provided MM-PBSA free-energies of binding clearly in
favor of cannabigerol, the evaluated free energy scores being −28 Kcal·mol−1 and −20 Kcal·mol−1 for
CBG and CBC (S stereoisomer), respectively.
Induced Fit docking experiments confirmed Glide results. In fact, docking poses with the
best score predicted by the Induced Fit protocol superimposed well with those obtained by Glide,
thus demonstrating that the predicted CBC and CBG binding modes were not affected by receptor
flexibility of InhA (see Figure S3 of the Supporting Information).
Based on these results, CBG turned out to be the best candidate for inhibition of InhA. In fact,
although CBC resulted structurally similar to the 5PP inhibitor according to the ligand-based analyses,
it could not be accommodated as good as CBG within the InhA enzyme with docking. To test this
prediction, CBG and CBC were purchased from Sigma-Aldrich (Milano, Italy) and then tested for
the inhibition of the InhA enzyme activity, as described in the “Material and Methods” section [36].
Notably, the experiments confirmed that CBG inhibits InhA with low micromolar inhibitory activity,
the evaluated IC50 being 5.2 ± 0.1 µM (see Table 1, and Figure S4 in the Supporting Information).
On the contrary, CBC turned out to be inactive or scarcely active (Table 1), in agreement with the
structure-based results.
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Table 1. Inhibitory activity of CBG and CBC. Triclosan was used as a positive control for the assays.
Compound % Inhibition at 50 µM IC50 (µM) a
CBG 78 5.2 ± 0.1
CBC 31 b nd
Triclosan (TCL) 100 (56% at 0.3 µM)
a The reported IC50 values are the mean of three experiments ± SD. b Not determined.
Finally, docking complexes were used to suggest which structural modifications of CBG
could potentially improve the activity of this cannabinoid. In particular, the substitution of the
3,7-dimethylocta-2,6-dienyl moiety of CBG with aromatic rings able to fit in the pocket lined by
Met98, Phe97, Pro99, Gln100, Met103 and Ala198 could improve binding to InhA [20,37,38]. Likewise,
substitutions of the n-pentyl moiety of CBG with cyclic aliphatic or aryl groups would provide
additional van der Waals contacts with the Phe149, Met155, Pro193, Ile215 and Leu218 residues, which
are expected to provide improved activity for InhA, as already observed for other InhA inhibitors [39].
3. Materials and Methods
3.1. Ligand-Based Virtual Screening on the DrugBank Database
Compounds with associated bioactivity annotations were first retrieved from the DrugBank
database (www.drugbank.ca, accessed on April 20, 2018) [18]. Then, compounds with recognized toxic
and reactive functional groups or transition metals, and a molecular weight lower than 150 or higher
than 850 Da were removed, yielding a database of 6014 unique compounds. The FILTER software
(OpenEye, Santa Fe, Mexico) was used for the filtering calculations [40]. Afterwards, all combinations
of stereoisomers, ionization states and tautomers potentially present at neutral pH were generated for
both the investigated cannabinoids and the filtered DrugBank ligands by using the Quacpac python
toolkits [41]. Pre-defined chiralities were kept unaltered and pre-treated structures were minimized
according to the MMFF force field [42]. Finally, up to 10 and 600 conformers were generated for the
investigated cannabinoids and the filtered DrugBank compounds, respectively. A cutoff of 0.5 Å on
RMSD and an energy window of 10 kcal/mol were used as parameters to accept conformers during the
conformational sampling with the OMEGA software [40,43].
A multi-conformer versus multi-conformer 3D shape-based virtual screening was performed
to evaluate the similarity profile of the investigated cannabinoids with respect to the filtered
DrugBank compounds. The ROCS software (version 3.2.1.4) was used as the engine for the similarity
calculations [25,44]. Finally, ligand alignments were visually inspected, and the activity annotations of
the DrugBank compounds were carefully analyzed.
3.2. Structure-Based Virtual Screening on Enoyl Acyl Carrier Protein (ACP) Reductase
The InhA crystal structure (PDB code: 2B36) was first downloaded and pre-processed with the
Protein Preparation Wizard module available within the Schrödinger Suite 2018-3 [20,45]. In particular,
atom types and bond connectivity issues in the downloaded crystal structure were fixed. Moreover,
missing side chains were rebuilt by using Prime (version 5.3) [46]. Then, hydrogen atoms were added
to the pre-treated crystal structures and their coordinates were energy-minimized. Finally, ions, solvent
and water molecules were removed.
Docking calculations were performed by using both Glide (version 8.0.012) and the Induced
Fit Docking protocol available within the Schrödinger Suite (New York, NY, USA) 2018-3 [27,28].
The NADH cofactor was included in the docking calculations and considered as a part of the receptor.
In the case of Glide, receptor grids were generated around the coordinates of the bound ligands (outer
box of 10 Å × 10 Å × 10 Å), with rigid docking calculations performed by using default settings.
Both the residues lining the protein-binding site and the NADH cofactor were considered as rigid
elements in the Glide calculations, while the “flexible” sampling mode was used for the ligand to
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determine the optimal ligand conformation and orientation (default settings). For each ligand, only the
pose with the best docking score was retained and visually inspected. In the case of Induced Fit
Docking, default settings were used for receptor grid generation, while the calculations for docking the
ligands into the 2B36 crystal structure were performed as follows. Firstly, the van der Waals radii of
the protein and ligand were scaled by a factor of 0.8, afterwards the compounds were docked into
the protein by using the default Glide SP protocol. Then, Prime was used to predict and optimize the
protein side chains around the ligand. In this stage of refinement, the residues within 5 Å of each
ligand pose were optimized, while the NADH cofactor was kept rigid. Other parameters were set to
the default. Finally, the poses were re-docked by using the Glide XP protocol and then scored. Twenty
poses with the best scores were retained for each ligand in the final step of the docking calculations to
be visually inspected.
The docking procedure was validated by redocking the co-crystallized 5PP ligand into its crystal
structure prior to the cannabigerol (CBG) and cannabichromene (CBC) screening. Afterwards, CBG
and CBC were prepared with LigPrep for the docking calculations [47]. In particular, all combinations
of stereoisomers, ionization states and tautomers potentially present at physiological pH in aqueous
solution were first generated and then minimized according to the OPLS_2005 force field [48]. Finally,
compounds were docked in the InhA active site. Moreover, the BEAR tool, which integrates molecular
dynamics and binding free energy estimations with the aim of refining ligand-protein complexes and
estimate binding energetics, was applied to further refine docking results obtained with Glide [31–35].
Default settings were used for rescoring the docking poses with BEAR [31]. A final step of visual
inspection of the generated poses confirmed the selection of CBG and CBC as potential candidate
inhibitors to be experimentally tested on InhA.
3.3. In Vitro Testing of the Compounds on the InhA Enzyme
CBG, CBC, NADH and the Triclosan standard control were purchased from Sigma-Aldrich. Stock
solutions of the investigated compounds were prepared in DMSO to let their final concentration be
equal to 5% v/v, in a final volume of 1 mL for all kinetic reactions. Kinetic assays were performed by
using trans-2-dodecenoyl-coenzyme A (DDCoA) and wild type InhA, as previously described [49].
Briefly, reactions were performed at 25 ◦C in an aqueous buffer (30 mM PIPES and 150 mM NaCl
pH: 6.8), containing additionally 250 µM cofactor (NADH), 50 µM substrate (DDCoA) and the tested
compound (at 50 µM or 10 µM). Reactions were initiated by addition of InhA (50 nM final) and NADH
oxidation was followed at 340 nm. The inhibitory activity of each derivative was expressed as the
percentage inhibition of InhA activity (initial velocity of the reaction) with respect to the control reaction
without inhibitor. Triclosan was used as the positive control. All activity assays were performed in
triplicate. For the most potent compound, IC50 values were determined by using the 4-parameter
curve-fitting software XLFit (IDBS), with at least six points.
4. Conclusions
In summary, we described the application of an integrated ligand-based and structure-based
in silico repositioning approach to identify potential targets of non-psychoactive cannabinoids.
The potential provided by the proposed approach was tested on cannabigerol (CBG) and
cannabichromene (CBC), leading to the identification of CBG as a low micromolar inhibitor of
the InhA enzyme. Indeed, naturally occurring cannabinoids are known to possess antibacterial activity
in various bacterial strains [17,50] but, to the best of our knowledge, their biological target(s) have
never been identified. Our study demonstrates that CBG is an InhA inhibitor. Interestingly, CBG is
a small molecular weight compound with a good safety profile. Therefore, it represents a valuable
starting point for the design of new synthetic derivatives with improved activity, thus paving the way
to novel interesting possibilities for the treatment of infectious diseases. Finally, our study showed
that integrating structure-based and ligand-based methods can lead to more accurate predictions
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of bioactive compounds [8]. This approach can be applied to efficiently repurpose any natural and
synthetic ligand towards other therapeutic targets of interest.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/24/14/2567/s1.
Figure S1: superimposition of the 5PP binding modes predicted by Glide and the Induced fit protocols with its
crystallographic conformation; Figure S2: superimposition of the predicted ligand-based and structure-based
(with Glide) poses of CBC; Figure S3: CBG and CBC binding modes predicted by the Induced Fit Docking protocol;
Figure S4: the dose-response curve of CBG on InhA; Table S1: similarity values obtained with ROCS of CBC and
CBG with respect to the DrugBank ligands.
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